133 related articles for article (PubMed ID: 18094856)
1. Pure neural leprosy: steroids prevent neuropathy progression.
Jardim MR; Illarramendi X; Nascimento OJ; Nery JA; Sales AM; Sampaio EP; Sarno EN
Arq Neuropsiquiatr; 2007 Dec; 65(4A):969-73. PubMed ID: 18094856
[TBL] [Abstract][Full Text] [Related]
2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
3. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
Gonçalves Hde S; Pontes MA; Bührer-Sékula S; Cruz R; Almeida PC; Moraes ME; Penna GO
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():74-8. PubMed ID: 23283457
[TBL] [Abstract][Full Text] [Related]
4. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
6. Borderline lepromatous leprosy presenting as a single cutaneous plaque.
Armour KS; Scolyer RA; Barnetson RS
Australas J Dermatol; 2005 Aug; 46(3):181-3. PubMed ID: 16008652
[TBL] [Abstract][Full Text] [Related]
7. Leprosy in a preschool child--a case report.
Arora SK
J Indian Med Assoc; 2007 Mar; 105(3):140. PubMed ID: 17824468
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
9. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
11. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
12. Severe type 1 upgrading leprosy reaction in a renal transplant recipient: a paradoxical manifestation associated with deficiency of antigen-specific regulatory T-cells?
Vieira AP; Trindade MAB; de Paula FJ; Sakai-Valente NY; Duarte AJDS; Lemos FBC; Benard G
BMC Infect Dis; 2017 Apr; 17(1):305. PubMed ID: 28438129
[TBL] [Abstract][Full Text] [Related]
13. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
14. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
15. Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients.
Mendis S; Somasiri KG; Chularatna W
Ceylon Med J; 1993 Dec; 38(4):174-7. PubMed ID: 8143332
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
18. Multidrug therapy (MDT) and leprosy control.
Noordeen SK
Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
[No Abstract] [Full Text] [Related]
19. Follow-up assessment of patients with Pure Neural Leprosy in a reference center in Rio de Janeiro-Brazil.
Pitta IJR; Hacker MAV; Andrade LR; Spitz CN; Vital RT; Sales AM; Antunes SLG; Sarno EN; Jardim MR
PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010070. PubMed ID: 35015773
[TBL] [Abstract][Full Text] [Related]
20. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
[Next] [New Search]
